More Videos
SPECIAL REPORT
MOST SHARED
- Future of Marketing
- Obama Sees Strains Unless US, China Balance Growth
- Oil Tomorrow
- Priceline Crushes Profit Forecasts; Shares Jump
- European Commission Objects to Sun Micro-Oracle Deal
- Mad Mail: Buy the Berkshire Hathaway Split?
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Sprint to Cut Up to 2,500 Jobs, Sees Charge
- A Year on, China's Stimulus Postpones its Problems
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Look Ahead: 'Risk On' Attitude Could Fuel Rally Further
- European Commission Objects to Sun Micro-Oracle Deal
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
- Do You Know Your Coca-Cola Myths?
- Electronic Arts Beats Street, Announces 1,500 Job Cuts
- Time Is Here to Look at Overseas Stocks: Bill Gross
RSS FEED
Pharma's Market
Text Size 
 |
AP Wyeth |
We just finished back-to-back coverage of the world's largest oncology and diabetes conferences. Now we get a bit of a break before shifting our attention to Alzheimer's.
Specifically, analysts say Wyeth [WYE
Loading...
()
]and Elan[ELN
Loading...
()
] could be out with basic results on a mid-stage test for their drug by the end of this month.
Then they're expected to present the detailed data at the International Conference on Alzheimer's Disease in late July. Some analysts think if the drug shows promise it could become the biggest selling drug in history.
Bill Tanner at Leerink Swann writes in a research note to clients today that "investors should not expect to see significant treatment effects given the relatively small size of the trial and the heterogeneity of the patients population." (Dear Elanians: I'm just reporting what the man said, please do not flood my inbox with complaints about what you might see as his bearish analysis.)
Nonetheless, he believes there will probably be enough positive data for the companies to continue to move forward. Coincidentally, Brian McCarthy, a biotech analyst at Merriman Curhan Ford initiated coverage today of ELN with a Buy rating.
But he agrees with Tanner about the pending test results. "We believe a statistically significant response in Phase 2 (mid-stage clinical trial) is unlikely given the small number of patients," McCarthy writes.
He justifies his Buy rating by saying, "Positive Phase 2 Alzheimer's data could add approximately $7 in the near-term, or approximately $15 longer term if (the drug) succeeds for AD."
But buyer beware. Both analysts also say that ELN shares could be volatile in the coming weeks.
Leerink Swann may trade ELN shares. Typically, if a company doesn't have any disclosures on a stock I won't mention it. I only point them out if they exist. But since MCF is initiating coverage today I will say it has none to make.
An estimates five million Americans have Alzheimer's. That number is expected to multiply.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes